ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 961

Microenvironment in Systemic Sclerosis Provides a Protective Niche for Tissue-resident B Cells During B Cell Depletion Therapy with Anti-CD20 Antibody

Ai Kuzumi1, Ayumi Yoshizaki 1, Takemichi Fukasawa 1, Satoshi Ebata 1, Yoshihide Asano 1 and Shinichi Sato 1, 1University of Tokyo Graduate School of Medicine, Department of Dermatology, Tokyo, Japan

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: B cells and B cell targeting, Systemic sclerosis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 11, 2019

Session Title: B Cell Biology & Targets In Autoimmune & Inflammatory Disease Poster

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: B cell depletion therapy with anti-CD20 antibody rituximab has emerged as a potential treatment for systemic sclerosis (SSc). Rituximab, which has been used to treat B cell malignancies and some autoimmune diseases, efficiently depletes circulating B cells. Tissue-resident B cells, on the other hand, have been shown to be more difficult to deplete, posing a therapeutic challenge. Resistance of tissue-resident B cells to rituximab has been associated with the inflammatory microenvironment in malignancy and autoimmunity, where B cell survival is promoted by various cytokines and chemokines. Among these survival factors, the following two have received much attention: CXCL12, a chemokine essential for the B cell niche in bone marrow, and B cell activating factor (BAFF), a cytokine promoting the survival of autoreactive B cells. In this study, we investigated the role of microenvironment on tissue-resident B cells during B cell depletion therapy with anti-CD20 antibody in SSc.

Methods: Bleomycin (BLM)-induced SSc model mice were treated with anti-CD20 antibody. AMD 3100, an antagonist of the CXCL12 receptor CXCR4, was used to block CXCL12. Anti-BAFF antibody was used to block BAFF. B cell depletion was assessed by flow cytometry in bone marrow, spleen, lymph nodes, lungs, and peripheral blood. Skin and lung fibrosis was evaluated histopathologically. CXCL12 and BAFF expression was quantified by qRT-PCR and immunofluorescence staining.

Results: While anti-CD20 antibody efficiently depleted circulating B cells and attenuated skin and lung fibrosis, a fraction of CD20+ B cells persisted in spleen, lymph nodes, and lungs of BLM-induced SSc model mice, contrasting with efficient depletion of tissue-resident B cells in control mice. Residual B cells showed increased expression of CXCR4. CXCL12 and BAFF expression was increased in skin and lungs of BLM-induced SSc model mice. Co-administration of anti-CD20 antibody with AMD3100 or anti-BAFF antibody enhanced the depletion of tissue-resident B cells. Furthermore, these combination therapies achieved greater attenuation of fibrosis in BLM-induced SSc model mice compared with anti-CD20 monotherapy.

Conclusion: SSc microenvironment provides a protective niche for tissue-resident B cells against anti-CD20 antibody. B cell survival factors like CXCL12 and BAFF are potential therapeutic targets that enhance the efficacy of B cell depletion therapy in SSc.


Disclosure: A. Kuzumi, None; A. Yoshizaki, None; T. Fukasawa, None; S. Ebata, None; Y. Asano, None; S. Sato, None.

To cite this abstract in AMA style:

Kuzumi A, Yoshizaki A, Fukasawa T, Ebata S, Asano Y, Sato S. Microenvironment in Systemic Sclerosis Provides a Protective Niche for Tissue-resident B Cells During B Cell Depletion Therapy with Anti-CD20 Antibody [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/microenvironment-in-systemic-sclerosis-provides-a-protective-niche-for-tissue-resident-b-cells-during-b-cell-depletion-therapy-with-anti-cd20-antibody/. Accessed April 13, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/microenvironment-in-systemic-sclerosis-provides-a-protective-niche-for-tissue-resident-b-cells-during-b-cell-depletion-therapy-with-anti-cd20-antibody/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.